(State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
VTV THERAPEUTICS INC. | |||||||||||
By: | /s/ Paul J. Sekhri | ||||||||||
Name: | Paul J. Sekhri | ||||||||||
Title: | President and Chief Executive Officer |
Cover |
Dec. 18, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Dec. 18, 2023 |
Entity Registrant Name | vTv Therapeutics Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-37524 |
Entity Tax Identification Number | 47-3916571 |
Entity Address, Address Line One | 3980 Premier Drive, Suite 310 |
Entity Address, City or Town | High Point |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 27265 |
City Area Code | 336 |
Local Phone Number | 841-0300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Class A common stock, par value $0.01 per share |
Trading Symbol | VTVT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001641489 |
L(5V1F8/2(5&0L JQ"(6,P$ "(" / " 5T0 !X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4 " !+@Y97)!Z;HJT #X 0 &@ @ &]
M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !+@Y97
M99!YDAD! #/ P $P @ &B$@ 6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08 "0 ) #X" #L$P !
end
RHY_U=3_ 102P,$
M% @ 2X.65Y>*NQS $P( L !?
\!_(;S%+M87 %>Y^^6E,.[C
M],N+P;W4$0*.#WBKF]Z05P/J8ZJ&&KN/7?6&?GS$+S4LLH+/!Q@63]UL09Z7
M'YSIJW4WI:$]P;3J9QVZMZ#"?0&I@E6TK)EV$O5^HJ]F"I+9Q[1(BH=3/?/E
M?/Y9WW#_;WB8^2YC'A88<9]21"3CB+(P1C&CKB"!&X,,9\7CH)Y!BKY?;/JO
M.CG0PZ2#;T6#1G-89K>Y?)K=%G/3E*5GJW)^H].4+V!YP] =H8.Q
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M-+6WKS@__CO G[7EF<("7)T6H$")%(,:3O)$CR$(07,8G#U@?;C3V,+0@\
MEF%7*!T-TREQ=B]'UXEL7Y>VIF>H G5;9JQJU4;O>Q6MZQ8'KUX;'3*5L